Fay Xing, partner at Wuxi Healthcare Ventures, the strategic investment arm of China-based pharmaceutical research company WuXi PharmaTech, joined one of the most active healthcare investors in May 2015.
Having spent nearly five years as a principal at Decheng Capital/Bay City Capital, based in Shanghai her move to Wuxi allowed her to add back US dealmaking to her China experience. She had earlier worked in corporate venture capital for Medtronic in the California and Shanghai after completing her MBA from Harvard in 2005 and two years working as founder of CardioCool in Palo Alto, California, during her doctor training at Stanford University.
In August, Wuxi was part of the $20m series C round for US-based cancer care technology developer Avelas Biosciences and participated in a $30m series D round for Israel-based digestible insulin formulation developer Nutrinia. In July, China-based biopharmaceutical startup CStone Pharmaceuticals closed a $150m series A round featuring WuXi Healthcare Ventures through one of Xing’s partners.